CBmed Wins 1st Place at Austria’s Leading Companies 2025
Following its regional success in Styria, CBmed has now achieved national recognition at the Austria’s Leading Companies (ALC) 2025 awards. At the gala held in Vienna, CBmed was awarded 1st place in the “Small Companies” category for the entire country, marking an important milestone in the company’s development.
The ALC awards, presented annually by Die Presse, KSV1870, and PwC, honor Austria’s most successful and future-oriented businesses. The national award reflects CBmed’s strong performance between 2022 and 2024, acknowledging its continued growth, international collaborations, and advancements in translational precision medicine.
Over the past years, CBmed has strengthened its position through pioneering work in multi-omics research, ex-vivo drug screening technologies, biomarker discovery, and its expanding network of partnerships across academia and industry. These developments are contributing to real-world impact in clinical research and supporting faster, more targeted therapeutic innovation.
This national award highlights CBmed’s role as a leading force in Austria’s life-science ecosystem and recognizes the dedication of the entire team as well as the company’s commitment to advancing precision medicine.
For more information about the ALC awards and the announcement, please visit Die Presse:
https://www.diepresse.com/20322100/weiterentwicklung-der-translationalen-medizin
And the ALC video from the gala night:
https://www.diepresse.com/unternehmen/alc
CBmed Wins 1st Place at Austria’s Leading Companies 2025
Following its regional success in Styria, CBmed has now achieved national recognition at the Austria’s Leading Companies (ALC) 2025 awards. At the gala held in Vienna, CBmed was awarded 1st place in the “Small Companies” category for the entire country, marking an important milestone in the company’s development.
The ALC awards, presented annually by Die Presse, KSV1870, and PwC, honor Austria’s most successful and future-oriented businesses. The national award reflects CBmed’s strong performance between 2022 and 2024, acknowledging its continued growth, international collaborations, and advancements in translational precision medicine.
Over the past years, CBmed has strengthened its position through pioneering work in multi-omics research, ex-vivo drug screening technologies, biomarker discovery, and its expanding network of partnerships across academia and industry. These developments are contributing to real-world impact in clinical research and supporting faster, more targeted therapeutic innovation.
This national award highlights CBmed’s role as a leading force in Austria’s life-science ecosystem and recognizes the dedication of the entire team as well as the company’s commitment to advancing precision medicine.
For more information about the ALC awards and the announcement, please visit Die Presse:
https://www.diepresse.com/20322100/weiterentwicklung-der-translationalen-medizin
And the ALC video from the gala night:
https://www.diepresse.com/unternehmen/alc